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Background: Chronic kidney disease has become a public health problem worldwide. Its terminal stage requires
renal replacement therapy – dialysis or transplantation – for the maintenance of life, resulting in high economic
and social costs. Though the number of patients with end-stage renal disease treated by dialysis in Brazil is among
the highest in the world, current estimates of incidence and prevalence are imprecise. Our aim is to describe
incidence and prevalence trends and the epidemiologic profile of end-stage renal disease patients receiving
publically-financed dialysis in Brazil between 2000 and 2012.
Methods: We internally linked records of the High Complexity Procedure Authorization/Renal Replacement Therapy
(APAC/TRS) system so as to permit analyses of incidence and prevalence of dialysis over the period 2000-2012. We
characterized temporal variations in the incidence and prevalence using Joinpoint regression.
Results: Over the period, 280,667 patients received publically-financed dialysis, 57.2% of these being male. The
underlying disease causes listed were hypertension (20.8%), diabetes (12.0%) and glomerulonephritis (7.7%); for
42.3%, no specific cause was recorded. Hemodialysis was the therapeutic modality in 90.1%. Over this period,
prevalence increased 47%, rising 3.6% (95% CI 3.2% - 4.0%)/year. Incidence increased 20%, or 1.8% (1.1% – 2.5%)/
year. Incidence increased in both sexes, in all regions of the country and particularly in older age groups.
Conclusions: Incidence and prevalence of end-stage renal disease receiving publically-financed dialysis treatment has
increased notably. The linkage approach developed will permit continuous future monitoring of these indicators.
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Chronic kidney disease has become a global public health
problem. The terminal stage of this condition, end stage
renal disease (ESRD), is a serious health outcome which
carries high economic and social costs, requiring renal re-
placement therapy in the form of dialysis or transplantation
in order to sustain life. The number of people with end-
stage renal disease starting renal replacement therapy has
increased worldwide in recent years, with a progressive* Correspondence: moural@paho.org
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unless otherwise stated.increase in the proportion being elderly [1,2]. In high-
income countries, end-stage renal disease accounts for a
substantial share of health care spending and is one of the
major contributors to rising health care costs. The annual
increase in spending for dialysis programs around the world
ranged from 6% to 12% over the last two decades and con-
tinues to grow, particularly in low- and middle-income
countries [3].
The increase in the number of individuals globally with
chronic kidney disease has stimulated the implementation
of public policies to address this condition. These in turn
require surveillance strategies designed to capture infor-
mation relevant to prevention and treatment. National,
local, or regional registries which collect and disseminate
information on end-stage renal disease are available inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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financed renal replacement therapy are reimbursed through
the High Complexity Procedure Authorization/Renal Re-
placement Therapy (Autorização de Procedimentos de Alta
Complexidade/Terapia Renal Substitutiva, or APAC/TRS)
subsystem of the Outpatient Information System (Sistema
de Informação Ambulatorial, or SIA) [4]. APAC/TRS re-
ceives and records data for the approximately 84.9% of dia-
lysis patients who are receiving treatment financed through
Brazil’s national health system (Sistema Único de Saúde, or
SUS) [5]. However, it has not been possible, to date, to
regularly monitor the incidence, prevalence, and mortality
of end-stage renal disease. Recently, we have created such a
unified database by linking patient records within this
APAC subsystem [4]. The aim of this study is to describe,
using this linked database, trends in incidence and preva-
lence and the epidemiological profile of patients with end-
stage renal disease receiving publically financed dialysis in
Brazil between the years 2000 to 2012.
Methods
We evaluated all patients with end stage renal disease
undergoing dialysis financed through the SUS between
January 1, 2000, and December 31, 2012, applying deter-
ministic and probabilistic record linkage techniques to
existing data files received from the Ministry of Health,
as has been previously described [4].
We defined a case of chronic end stage renal disease as
an individual for whom reimbursement was solicited via
APAC/TRS for a minimum of three months, thus minim-
izing the possible inclusion of patients with acute renal
failure not requiring chronic dialysis [6].
We produced descriptive analyses of dialysis patients
sex, age, race/color (as ethnicity is officially characterized
in Brazil), region of residence, underlying disease, and
treatment modality. The race/color “brown”, or “pardo” in
Portuguese, permits individuals to self-identify as of a
mixed race, “black” referring basically to those who self-
identify as being predominantly of African ancestry;
“yellow” refers to those of Asian background, these pre-
dominantly being of Japanese ancestry [7]. To define the
underlying disease that led to end stage renal disease we
used a classification consisting of six groups based on
codes from the International Statistical Classification of
Diseases and Related Health Problems - Tenth Revision
(ICD-10): diabetes mellitus, hypertension, glomeruloneph-
ritis, chronic interstitial nephritis, other diseases, and end-
stage renal disease of uncertain cause [6]. Those with
missing ICD-10 codes were excluded from this specific
analysis.
Incidence and prevalence were expressed per 1,000,000
inhabitants/year (patients per million population, or pmp),
using population data from the 2000 and 2010 demo-
graphic censuses and official interpolations for intercensusyears [8]. As we could not distinguish new from prevalent
cases in 2000, we defined incident cases from 2001 onwards.
We used Joinpoint regression for analysis of trends in
the incidence of end-stage renal disease [9]. This regres-
sion analysis identifies the point at which statistically sig-
nificant changes in tendencies occur over time, and then
expresses the annual percent change (APC) and its 95%
confidence interval over each separate temporal segment
identified. Changes in trends may be either in magnitude
or direction. A negative sign indicates a decline over a
temporal segment.
Basic analyses were performed using Statistical Analysis
System - SAS. Microsoft Excel was used for the calculation
of incidence and prevalence. This study was approved
by the Ethics in Research Committee of the Hospital de
Clínicas de Porto Alegre on 10/03/2010 (No. 100056). As
analyses are based on surveillance databases from the
Ministry of Health, no patient consent was necessary. All
those with access to data signed agreements to maintain
the confidentiality of the information.
Results
Over the period studied, a total of 280,667 patients with
end-stage renal disease received publically-financed dialy-
sis for at least 3 consecutive months. Of these 160,569
(57.2%) were males and 120,098 (42.8%) females. As
Table 1 shows, most (72.6%) cases were treated in the
southeast and northeast regions. The predominant age
grouping was 45-64 years (43.4% of patients), with 29.9%
of those treated being <44 years old, and 26.8% ≥ 65. In
terms of race/color categories, for which information was
available from 2008 on, 45.2% were registered as white, 9.7%
as black, 30.8% as brown, 0.8% yellow (Asian) and 0.2%
native Brazilian. After excluding 10924 cases with missing
ICD-10 codes, the principal underlying causes of renal fai-
lure were hypertension (20.4%), diabetes mellitus (12.0%)
and glomerulonephritis (7.7%). For 42.3% of patients, the
cause was listed as “undetermined”. The predominant
therapeutic modality (90.1%) was hemodialysis.
Table 2 shows the annual increase in prevalence of
patients in dialysis from 2000 to 2012. Joinpoint re-
gression indicated an average annual increase of 3.6%
(95% CI 3.2% – 4.0%). The average annual increase in inci-
dence was more discrete – 1.8% (1.1% – 2.5%)/year.
Trends in the incidence of dialysis, expressed as the
annual variation in incidence as estimated by the Join-
point software, are presented by geographical region
and sex in Table 3. One notes an increase in incidence
in both men and women in all regions of the country,
although slightly less so in the south, where the increase
among males was 1.2% (0.2% – 2.2%) and among fe-
males 0.2% (-0.6% – 1.0%). Except in the north region,
the increase was always greater in males. When the esti-
mated trend varied in a statistically significant way over
Table 1 Demographic and clinical characteristics of the 280,667 patients with chronic end-stage renal disease receiving
publically-financed dialysis covering a period of at least 3 consecutive months
Characteristic Total Males Females
n % n % n %
Geographic region*
North 11874 4.2 6791 4.2 5079 4.2
Northeast 59688 21.3 34867 21.7 24799 20.7
Southeast 144242 51.4 82057 51.1 62134 51.8
South 46322 16.5 26145 16.3 20161 16.8
Center-west 18538 6.6 10709 6.7 7822 6.5
Total 280664 100 160569 100 119995 100
Age (years)*
0 - 19 9607 3.4 5176 3.2 4430 3.7
20 - 44 74163 26.5 39975 24.9 34188 28.5
45 - 64 121584 43.4 71487 44.6 50097 41.8
65 - 74 48175 17.2 27910 17.4 20265 16.9
75 e + 26811 9.6 15902 9.9 10909 9.1
Total 280340 100.0 160450 100 119889 100
Race/skin color**
White 46014 45.2 27026 45.8 18988 44.3
Black 9897 9.7 5556 9.4 4341 10.1
Brown 31386 30.8 18100 30.7 13286 31.0
Yellow (Asian) 835 0.8 493 0.8 342 0.8
Native Brazilian 199 0.2 110 0.2 89 0.2
Lacking information 13484 13.2 7669 13.0 5815 13.6
Total 101815 100 58954 100 42861 100
Underlying disease*
Undetermined 118349 42.3 68014 42.5 50335 42.1
Diabetes 33692 12.0 18466 11.5 15226 12.7
Hypertension 57166 20.4 33440 20.9 23726 19.8
Glomerulonephritis 21459 7.7 12172 7.6 9287 7.8
Chronic interstitial nephritis 7308 2.6 4321 2.7 2987 2.5
Other 41747 14.9 23671 14.8 18076 15.1
Total 279721 100 160084 100 119637 100
Therapeutic modality*
Hemodialysis 250183 90.1 144992 91.2 105095 88.5
Peritoneal dialysis 27648 9.9 13960 8.8 13681 11.5
Total 277831 100 158952 100 118776 100
Brazil, 2000 to 2012.
*Small diferences in totals are due to missing data for specific variables.
**Data available from 2008 onward.
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each temporal segment is shown.
Similarly, specific trends for different age/sex groupings
are shown in Table 4. Incidence fell over the period for
younger Brazilians (ages 0-19 and 20-44). For 0-19 year old
males, the decline was -2.3% (-3.5% – 1.1%)/year, and for
men 20-44, -1.1% (-1.8% – -0.3%)/year. For females thedecline was -1.1% (-2.4% – 0.2%)/year and -0.8 (-1.5% –
0.0%), for the 0-19 and 20-44 age groups, respectively. Older
men (45-64, 65-74 and 75+) presented annual increases of
0.9% (0.2% – 1.7%), 2.3% (1.6% – 3.0%) and 3.0% (2.0% –
4.1%), respectively. Incidence in women declined in the 45-
64 age range, increased slightly for those between 65-74 and
increased 2.2% (1.1% – 3.4%) for those 75 or over.
Table 2 Prevalence and incidence of publically-financed dialysis for end stage renal disease covering at least three
consecutive months
Prevalence Incidence
Year Population n Coefficient (pmp) Annual change (%) n Coefficient (pmp) Annual change (%)
2000 169799848 57105 336.3 _
2001 171705916 62891 366.2 8 .9 15788 91.9
2002 173704941 65324 376.0 2 .7 15859 91.2 -0 .8
2003 175730799 70619 401.8 6 .9 17210 97.9 7 .3
2004 177783157 74083 416.7 3 .7 17712 99.6 1 .7
2005 179863161 78371 435.7 4 .6 18091 100.5 0 .9
2006 181971226 82265 452.0 3 .7 18395 101.0 0 .5
2007 184107444 85851 466.3 3 .2 18691 101.5 0 .5
2008 186272178 85521 459.1 -1 .5 17530 94.1 -7 .3
2009 188466163 91361 484.7 5 .6 19706 104.5 11 .1
2010 190755799 95918 502.8 3 .7 20691 108.4 3 .7
2011 192943315 100614 521.4 3 .7 21885 113.4 4 .6
2012 193976530 104433 538.3 3 .2 22004 113.4 0 .0
Brazil, 2000 to 2012.
Sources: APAC; Instituto Brasileiro de Geografia e Estatística – IBGE (4).
pmp = patients per 1 million population.
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Our results, based on national data of renal dialysis in the
national health system, estimated to cover 85% of Brazilian
patients in dialysis, illustrate the growing importance of
ESRD in Brazil. From 2000 to 2012, the prevalence of
ESRD receiving dialysis increased by 46.8%, an average of
3.6% per year, and the incidence by 20%, an average of 1.8%
per year. By 2011, the most recent year with complete as-
certainment, a total of 521.4 cases pmp existed, of which
113.4 cases pmp had initiated treatment that year.
To date, considerable uncertainty has existed as to inci-
dence and prevalence of patients with ESRD undergoing
dialysis in Brazil. Frequently cited data have come from an
annual query of the Brazilian Nephrology Society to its
members. However, as reporting through this query is vol-
untary and incomplete, with only 55% of dialysis centersTable 3 Trends in the incidence of publically-financed
dialysis for end stage renal disease covering a minimum
of 3 consecutive months, by geographic region and sex
Region Males Females
APC* (IC 95%) APC* (IC 95% )
Brazil 2.1 (1.4-2.9) 1,3 (0.6- 2.1)
North 3.8 1.5 – 6.2) 3.8 (2.0 – 5.6)
Northeast 4.1 (3.6 – 4.7) 3.5 (2.6 – 4.4)
Southeast 1.4 (0.7 – 2.1) 0.6 (-0.2 – 1.4)
South 1.2 (0.2 – 2.2) 0.2 (-0.6 – 1.0)
Center-west 3.5 (2.4 – 4.6) 2.6 (1.4 – 3.8)
Brazil, 2001 to 2012.
*Annual percentage change (APC).responding in 2011, uncertainty regarding the exact num-
bers remains. In fact, our APAC prevalence estimate for
2011 (521 pmp), is greater than the Society’s (475 pmp)
[5]. The true difference is even greater, as APAC covers
only publically financed treatment, roughly 85% of all dia-
lysis, and our analyses excluded patients on dialysis for less
than 3 months [5]. Further, in terms of estimating total
cases of ESRD, neither the frequencies here reported, nor
those of the Brazilian Nephrology Society include patients
who die of ESRD before receiving renal replacement ther-
apy or patients undergoing transplantation without previ-
ous dialysis for at least three months.
In any event, by international comparison, a massive
number of patients receive dialysis in Brazil. Grassmann et
al, in their global overview of ESRD, placed Brazil among
countries with the greatest number of patients receivingTable 4 Trends in the incidence of publically-financed
dialysis for end stage renal disease covering a minimum
of 3 consecutive months, by age and sex
Age (years) Males Females
APC* (IC 95%) APC (IC 95%)
0 – 19 -2.3 (3.5 – -1.1) -1.1 (-2.4 – 0.2)
20 - 44 -1.1 (-1.8 – -0.3) -0.8 (-1.5 – 0.0)
45 – 64 0.9 (0.2 – 1.7) -0.4 (-1.1 – 0.3)
65 - 74 2.3 (1.6 – 3.0) 0.4 (-0.6 – 1.4)
75 + 3.0 (2.0 – 4.1) 2.2 (1.1 – 3.4)
Brazil, 2001 to 2012.
*Annual percentage change (APC).
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(USRDS), which estimated a prevalence of renal dialysis of
679 pmp in 2011 for Brazil, ranked the country third in
the world for that year in terms of numbers of patients
undergoing dialysis [10].
This position is in large part due to the size of the popu-
lation, as prevalence rates are at the low end of the
spectrum shown in the USRDS’s international compari-
sons. Approximately half of the countries listed by the
USRDS, in general high income countries, had prevalence
rates of >1000 pmp. The relatively lower prevalence in
Brazil may well reflect remaining problems of access to
therapy. According to a recent publication of the Latin
American Dialysis and Renal Transplant Registry (RLDTR),
prevalence and incidence are increasing across the region.
Several South American countries have dialysis prevalence
in 2008 - Argentina (620 pmp) Chile (852 pmp) and
Uruguay (825 pmp) - greater than those we report (459
pmp) for that year, with the overall prevalence for the re-
gion (461 pmp) being quite similar to ours [11]. Of note,
however, these comparisons are not adjusted for age, and
many of the countries with higher rates of dialysis, espe-
cially the high income countries, have a more elderly popu-
lation. The prevalence of ESRD treated by dialysis in Brazil
is likely to continue to increase, since the transplantation
rate is around 26 pmp/year in Brazil and crude mortality is
lower than 20% [12].
In terms of modality of dialysis, only 10%, of publically
financed patients are currently receiving peritoneal dialy-
sis. The fraction so treated varies tremendously across
countries, with most countries having a frequency of peri-
toneal dialysis not too different from that of Brazil [10].
The discrete increase in the incidence of patients receiv-
ing dialysis from 2001 to 2012 was present in all regions
of the country, though less so in the southeast and south,
and may reflect growing access to treatment. The increase
was greater in women and in the older age strata, where
diabetes and hypertension present as the principal causes
of ESRD. A notably larger increase in this age group was
also reported in Canada a decade ago [13]. More recent
series in the in the U.S. noted a larger increase in the 45 to
64 year age range [14].
The analysis of the underlying cause of ESRD in APAC
is limited by the high percentage (42.3%) of diagnoses
listed as indeterminate, the percentage being as high as
80% among native Brazilian patients. Among specific diag-
noses listed, hypertension (20.4%) was the principal cause,
followed by diabetes (12%) and then by glomerulonephritis
(7.7%). These results are similar to those reported for the
period of 2000-2004 by Cherchiglia et al. [15]. The pattern
of hypertension and diabetes as predominant causes is
typical of high and medium income countries, with varia-
tions in the relative positions of hypertension and diabetes.
In contrast, glomerulonephritis is the more prevalentcause of ESRD in low income countries, comprising 25-
35% of causes. Diabetes has been cited as the cause of
ESRD in 9.1 to 29.9% of patients in different countries in
the developing world, and hypertension in 13 to 21% [16].
The USRDS report shows a quite variable proportion,
from 15 to 60%, of diabetes as a cause across surveyed
countries [10]. Given the multicausal nature of ESRD, it is
to be expected that diabetes and hypertension frequently
overlap in the causal process, and this uncertainty may ex-
plain, in part, the high frequency of indeterminate cause
listed in the APAC system.
Data on race/color of dialyzed patients, to our know-
ledge, have not been previously published in Brazil. Re-
ported patient race/color, after redistribution of those
lacking information uniformly across the race/color cat-
egories, is predominantly white (52%), followed by brown
(35%), black (11%), Asian (0.9%) and native Brazilian
(0.2%). These proportions are similar to the self-declared
information on race/color presented in the 2010 census:
white 47.7%, brown 43.1%, black 7.6%, Asian 1.0% and na-
tive Brazilian 0.4% [8].
The major strength of our study is that the database cre-
ated permits analysis of a consistent series of several years
of all publically-financed dialysis in Brazil, instead of rely-
ing on non-representative sampling with incomplete
reporting. Aside from serving as the basis for the results
here reported, this database will permit future analyses, in-
cluding economic ones and those related to assessment of
disease burden.
Limitations to these results merit a brief discussion.
As APAC does not adequately estimate the prevalence
and incidence of renal transplantation, caution is required
in using these data to estimate the total number of pa-
tients receiving renal replacement therapy in Brazil, and
further work is necessary to achieve estimates of ESRD in-
cidence and prevalence. In this regard, approximately 28.4
patientspmp received a renal transplant in Brazil in 2012
[12]. As the majority of these were receiving dialysis for
more than 3 months prior to receiving their transplant,
underestimation of incidence of ESRD receiving renal re-
placement therapy is likely to be small.
Another important limitation relates to the coding of
the underlying cause of renal failure, as previously
noted. Similarly, though the introduction of reporting
race/color of patients is an important advance, the high
frequency of missing data limit precision in the report-
ing of this characteristic.
In summary, these analyses demonstrate the importance
of the APAC system as a source for surveillance of the
treatment of ESRD in Brazil. Assuming current incidence
rates and lethality, the trends here presented indicate that
the total number of cases needing publically financed renal
dialysis will increase considerably. Given that renal re-
placement therapies have been reported to represent 8%
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increase will demand adequate planning of resources [17].
In terms of surveillance, continued analysis of the
APAC system can provide important findings for public
policies regarding the prevention, control and treatment
of ESRD at local, regional and national levels. Actions
and more detailed investigations should be undertaken
to further qualify available data, especially with respect
to the underlying causes of ESRD in Brazil. In this re-
gard, the Brazilian Society of Nephrology has joined
with the Ministry of Health in stimulating and support-
ing the adoption of effective measures for the surveil-
lance, prevention, treatment and management of kidney
disease in order to reduce its impact in terms of popula-
tion health. The main goals within this effort are to in-
crease awareness of risk factors for chronic kidney
disease and of the importance of its complications [18].
Conclusions
In conclusion, the epidemiologic profile for ESRD receiving
dialysis in the SUS between 2000 and 2012 demonstrates a
discrete yet constant increase in incidence and a larger in-
crease in prevalence, especially in older individuals. Over
this period, the number of individuals receiving renal dia-
lysis almost doubled. These figures parallel global trends,
suggesting that health care expenditures in dialysis will
continue to increase in the foreseeable future, and high-
light the importance of preventive measures, especially
those related to the prevention and control of the main
underlying causes of ESRD – hypertension and diabetes.
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